Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Oral Antipsychotic
09 juil. 2024 07h53 HE
|
Celon Pharma
-Statistically significant benefit demonstrated in primary endpoint of positive subscale of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) at Week 4- -Dose-response was...
Celon Pharma Announces Results of Phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)
17 juin 2024 16h05 HE
|
Celon Pharma
KIELPIN, Poland, June 17, 2024 (GLOBE NEWSWIRE) -- Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase 2 trial a JAK/ROCK dual inhibitor in the treatment of Rheumatoid...
Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes
22 juin 2021 12h45 HE
|
Celon Pharma
KIELPIN, Poland, June 22, 2021 (GLOBE NEWSWIRE) -- Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL’280, its second generation GPR40 agonist in type 2...
Celon Pharma Hosting a Virtual Capital Markets Day on Wednesday, April 21st
19 avr. 2021 08h00 HE
|
Celon Pharma
KIELPIN, Poland, April 19, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced that it will host a virtual Capital Markets Day to be held on Wednesday, April 21, 2021 at 10:00 AM ET. The...
Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial
01 avr. 2021 03h30 HE
|
Celon Pharma
KIELPIN, Poland, April 01, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of a Phase 1 trial of its second generation GPR40 agonist, CPL’280. This agent is in...
Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor
10 févr. 2021 09h00 HE
|
Celon Pharma
KIELPIN, Poland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was...
Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression
08 janv. 2021 14h16 HE
|
Celon Pharma
KIELPIN, Poland, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation)...